Graft Function Clinical Trials

1 recruiting

Graft Function Trials at a Glance

11 actively recruiting trials for graft function are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in São Paulo, New York, and Guangzhou. Lead sponsors running graft function studies include Apellis Pharmaceuticals, Inc., Beijing Friendship Hospital, and Alexion Pharmaceuticals, Inc..

Browse graft function trials by phase

Treatments under study

About Graft Function Clinical Trials

Looking for clinical trials for Graft Function? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft Function trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft Function clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Kidney TransplantDelayed Graft FunctionDGF
Alexion Pharmaceuticals, Inc.450 enrolled130 locationsNCT06830798
Recruiting
Phase 1Phase 2

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Ischemia Reperfusion InjuryDelayed Graft Function
Rhode Island Hospital20 enrolled1 locationNCT04005469
Recruiting
Not Applicable

Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study)

Graft Function
Medical University of Vienna100 enrolled2 locationsNCT07516990
Recruiting
Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

End Stage Renal DiseaseDelayed Graft FunctionDeceased Donor Kidney Transplant
Apellis Pharmaceuticals, Inc.320 enrolled1 locationNCT07020832
Recruiting
Phase 1Phase 2

The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

Kidney TransplantationDelayed Graft Function
First Affiliated Hospital of Chongqing Medical University47 enrolled2 locationsNCT07275632
Recruiting
Not Applicable

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

Graft FailurePoor Graft Function
NYU Langone Health21 enrolled1 locationNCT06569082
Recruiting
Not Applicable

Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation

Kidney TransplantDelayed Graft Function
Beijing Friendship Hospital150 enrolled1 locationNCT06855758
Recruiting
Phase 1

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Poor Graft Function
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06792682
Recruiting
Phase 3

Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys

Kidney Transplant; ComplicationsIschemia Reperfusion InjuryDelayed Graft Function+1 more
Cliniques universitaires Saint-Luc- Université Catholique de Louvain60 enrolled1 locationNCT05430620
Recruiting
Not Applicable

Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

End Stage Renal DiseaseKidney TransplantationDelayed Graft Function
RenJi Hospital380 enrolled3 locationsNCT06367205
Recruiting
Phase 2

REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT) Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia

One of the health conditions being studied in this trial will be Poor Graft FunctionOne of the health conditions being studied in this trial will be Aplastic Anaemia
The Royal Melbourne Hospital20 enrolled1 locationACTRN12620001339943